For those who haven’t yet seen this, this occurred a few days ago. Apparently this patient’s lymphoma was very advanced. There seems to be a high correlation between degree of disease and severity of Cytokine Release Syndrome (CRS). We’ll have to wait and see what this means for Kite Pharmaceuticals’ request for FDA approval for their CAR-T program.
One of Kite Pharma’s CAR-T patients died from cerebral edema, triggering a safety alarm – ENDPOINTS NEWS
Kite CAR-T Death: An Unwelcome Mystery as FDA Mulls Approval | Xconomy
Kite Pharma Discloses CAR-T Patient Death, Rattling Investors – TheStreet
Investors spooked by Kite CAR-T death, but biotech remains confident | FierceBiotech